|
Fig. 1. What Venture Capital investors and Multinational partner company licensing negotiators look for in biotechnology companies. Summary of Ernst and Young survey of the fraction of Venture Capital investors (left) and Multinational partner company licensing negotiators (right) who have stated that specific aspects of a biotechnology company are essential to consideration of funding or collaborating with them respectively. Length of bar is proportional to percentage who considered this aspect important.
|
